Aerovate Therapeutics ROE 2020-2024 | JBIO
Current and historical return on equity (ROE) values for Aerovate Therapeutics (JBIO) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Aerovate Therapeutics ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-12-31 |
$-0.07B |
$0.08B |
-80.94% |
| 2024-09-30 |
$-0.08B |
$0.08B |
-89.84% |
| 2024-06-30 |
$-0.09B |
$0.09B |
-83.81% |
| 2024-03-31 |
$-0.08B |
$0.09B |
-70.09% |
| 2023-12-31 |
$-0.08B |
$0.11B |
-62.04% |
| 2023-09-30 |
$-0.07B |
$0.13B |
-55.91% |
| 2023-06-30 |
$-0.07B |
$0.14B |
-49.90% |
| 2023-03-31 |
$-0.06B |
$0.11B |
-43.77% |
| 2022-12-31 |
$-0.05B |
$0.13B |
-35.92% |
| 2022-09-30 |
$-0.05B |
$0.14B |
-28.85% |
| 2022-06-30 |
$-0.04B |
$0.15B |
-22.26% |
| 2022-03-31 |
$-0.03B |
$0.16B |
-25.20% |
| 2021-12-31 |
$-0.02B |
$0.17B |
-29.30% |
| 2021-09-30 |
$-0.02B |
$0.18B |
-58.91% |
| 2021-06-30 |
$-0.02B |
$-0.02B |
117.65% |
| 2021-03-31 |
$-0.01B |
$-0.02B |
151.72% |
| 2020-12-31 |
$-0.01B |
$-0.01B |
276.92% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.008B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
